

GP 1614
JLW

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/807,620	
	Filing Date	March 24, 2004	
	First Named Inventor	Jessie L.S. Au	
	Art Unit	1614	
	Examiner Name		
Total Number of Pages in This Submission	5	Attorney Docket Number	TNI 2-011

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks Cited References Forms 1449	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Gerald L. Smith Mueller and Smith, LPA
Signature	
Date	September 17, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Jane Keeney		
Signature		Date	September 17, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Jessie L.S. Au, *et al.*
Serial No. : 10/807,620
Filed: : March 24, 2004
For: : METHODS AND COMPOSITION TO DETERMINE THE
CHEMOSENSITIZING DOSE OF SURAMIN USED IN
COMBINATION THERAPY.

TC/AU : 1614
Examiner :
Attorney Docket No. : TNI 2-011

MAIL STOP PATENT APPLICATION
HONORABLE COMMISSIONER FOR PATENTS
P.O. Box 1245
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is filed in conformity with 37 C.F.R. §§ 1.56, 1.97 and 1.98. Accordingly, copies of the art cited herein are provided. The following list of patents and publications is being submitted in addition to form PTO-1449 to assist the Examiner in the consideration of the cited disclosures.


1. United States Patent No. 6,599,912 B1 by Au et al., entitled "Methods and compositions for modulating cell proliferation and cell death," dated July 29, 2003.
2. PCT publication WO 2003/026574 A3 by Au et al., entitled "Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy," dated April 3, 2003.
3. EDWARDS, A., et al., "Surface area nomogram for a cytotoxic drug regimen: computerized model." Pharm. J. (England) 225: 674-675 (December 13, 1980).
4. SONG, S., et al., "Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases." Can. Res. 61(16): 6145-6150 (August 15, 2001).
5. TU, S., et al., "Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer." Clin. Can. Res. 5(5): 1193-1201 (May 4, 1998).

It respectfully is submitted that none of the foregoing art, alone or in combination, shows or proposes the present invention. Accordingly, favorable action on the application respectfully is requested.

Respectfully submitted,

Date:

17 Sept 04

A handwritten signature in black ink, appearing to read 'G. L. Smith', is written over a horizontal line.

Gerald L. Smith
Reg. No. 22,009
MUELLER AND SMITH, L.P.A.
MUELLER-SMITH BUILDING
7700 Rivers Edge Drive
Columbus, Ohio 43235-1355
Tel.: 614-436-0600
Fax: 614-436-0057
email: jsmith@muellersmith.com



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/807,620
		Filing Date	March 24, 2004
		First Named Inventor	Jessie L.S. Au
		Art Unit	1614
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number TNI 2-011	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		EDWARDS, A., et al., "Surface area nomogram for a cytotoxic drug regimen: computerized model." Pharm. J. (England) 225: 674-675 (December 13, 1980).	
		SONG, S., et al., "Nontoxic doses of suramin enhanced activity of paclitaxel against lung metastases." Can. Res. 61(16): 6145-6150 (August 15, 2001).	
		TU, S., et al., "Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer." Clin. Can. Res. 5(5): 1193-1201 (May 4, 1998).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.